BlossomHill Therapeutics (NASDAQ:BLSM) Reaches New 12-Month High – Time to Buy?

BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) reached a new 52-week high during mid-day trading on Friday . The company traded as high as $20.62 and last traded at $19.80, with a volume of 45887 shares traded. The stock had previously closed at $20.02.

Key Stories Impacting BlossomHill Therapeutics

Here are the key news stories impacting BlossomHill Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating and a $35 price target, representing substantial potential upside from recent trading levels. Its estimates show quarterly losses narrowing from $0.92 per share in Q3 2026 to $0.69 per share by Q3–Q4 2027, while the projected full-year loss improves from $3.71 in 2026 to $2.99 in 2027. HC Wainwright earnings estimates and rating
• Positive Sentiment: BlossomHill announced upcoming presentations at the RAS-Targeted Drug Development Summit and the H.C. Wainwright Global Investment Conference. The events could increase investor awareness of its oncology pipeline and development strategy. BlossomHill conference presentation announcement
• Positive Sentiment: Several firms—including HC Wainwright, Guggenheim, Leerink Partners, LifeSci Capital and JPMorgan—recently initiated or expanded research coverage. Broader analyst attention can improve institutional visibility and trading interest. New analyst coverage
• Neutral Sentiment: Zacks Research upgraded its view of BLSM to Hold. The change suggests a more constructive stance than its prior rating, but a Hold is not a clearly bullish recommendation. Zacks rating update
• Negative Sentiment: Despite expected improvement, HC Wainwright still forecasts sizable losses through 2027, indicating that BlossomHill is not yet profitable and may remain dependent on financing or successful clinical development.

Wall Street Analysts Forecast Growth

BLSM has been the subject of several research analyst reports. Lifesci Capital began coverage on BlossomHill Therapeutics in a research note on Tuesday. They set an “outperform” rating and a $32.00 price target for the company. Guggenheim started coverage on shares of BlossomHill Therapeutics in a report on Tuesday. They issued a “buy” rating and a $30.00 price objective for the company. Zacks Research raised shares of BlossomHill Therapeutics to a “hold” rating in a report on Wednesday. HC Wainwright initiated coverage on shares of BlossomHill Therapeutics in a research report on Tuesday. They set a “buy” rating and a $35.00 price target for the company. Finally, JPMorgan Chase & Co. assumed coverage on BlossomHill Therapeutics in a research note on Tuesday. They issued an “overweight” rating and a $28.00 target price for the company. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $32.20.

BlossomHill Therapeutics Stock Down 0.8%

Insider Buying and Selling

In other news, Director Orbimed Advisors Llc acquired 625,000 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was acquired at an average price of $16.00 per share, for a total transaction of $10,000,000.00. Following the completion of the acquisition, the director owned 2,714,279 shares in the company, valued at $43,428,464. This trade represents a 29.91% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, General Counsel Vincent Liptak bought 2,200 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were acquired at an average price of $16.00 per share, for a total transaction of $35,200.00. Following the acquisition, the general counsel owned 111,412 shares in the company, valued at approximately $1,782,592. This represents a 2.01% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought 1,573,900 shares of company stock valued at $25,181,900 over the last 90 days.

About BlossomHill Therapeutics

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.